Simulations Plus, Inc.(NASDAQ: SLP – News), a leading provider of software for pharmaceutical discovery and development, today announced that it has received a purchase order from the U.S. Food and Drug Administration (FDA) to license the Company’s ADMET Predictor™ software.
Ron Creeley, vice president of marketing and sales for Simulations Plus, said: “We’re very pleased that the FDA’s Cardiovascular and Renal Products division has licensed our best-in-class ADMET Predictor software with all four of its modules. ADMET Predictor predicts almost 80 properties of molecules with only their molecular structure as input, including physicochemical, biopharmaceutical, metabolism, toxicity, and some activity properties. The program has been consistently ranked first in accuracy in published comparison studies with competitive programs. We’ve enjoyed our relationships with numerous FDA researchers over the years and look forward to continuing to support the part of the FDA’s Critical Path Initiative that calls for continuous improvements in modeling and simulation software for pharmaceutical research.”